



# Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



March 15, 1997  
Volume 57 • Number 6  
PP. 1007-1216  
ISSN 0008-5472 • CNREA 8

**THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PRESENTS**

***Three Outstanding Training Opportunities  
Supported by Major Grants from the National Cancer Institute  
Primarily for Postdoctoral and Oncology Fellows***

Waiver of Registration Fees and Partial Subsidy of Lodging and Subsistence Expenses for Qualified Fellows

---

**Molecular Biology in Clinical Oncology**

*A thorough overview of concepts in molecular biology designed for clinical oncologists in training*

June 27-July 3, 1997, The Given Biomedical Institute, Aspen, CO  
Stephen H. Friend, L. Michael Glodé, and Jennifer A. Pietenpol, Organizers

- Lectures by leading experts on molecular biology concepts and the latest developments in molecular oncology
  - Small group laboratory sessions to demonstrate the important experimental techniques utilized in molecular biology
  - Career development session and scheduled networking opportunities
  - Application Deadline: March 31, 1997
- 

**Molecular Biology and Pathology of Neoplasia**

(formerly entitled **Histopathobiology of Neoplasia**)

The Edward A. Smuckler Memorial Workshop

*Intensive training in the molecular biology and morphology of human cancer for graduate students and postdoctoral fellows contemplating careers in basic cancer research*

July 6-13, 1997, Keystone Resort, Keystone, CO  
Robert Low, Course Director

- Twenty-eight hours of hands-on laboratory exercises directed by distinguished pathologists
  - An outstanding series of lectures on rapidly developing areas of cancer research by laboratory directors and other prominent investigators
  - Poster presentations by students and faculty to facilitate further scientific exchange
  - Application Deadline: April 30, 1997
- 

**Methods in Clinical Cancer Research**

Co-Sponsored by the American Society of Clinical Oncology (ASCO)

*The essentials of clinical trials design for researchers at the level of fellow or junior faculty*

July 26-August 1, 1997, Vail Cascade Resort and Club, Vail, CO  
Daniel D. Von Hoff and Charles A. Coltman, Jr., Chairpersons

- A series of lectures by leaders in the field covering all elements of clinical trials design
  - Small group discussion sessions on important techniques in clinical research
  - Development of a clinical trial protocol by all participants with detailed critiques by faculty members
  - Category I CME credits through ASCO
  - Application Deadline: April 21, 1997
- 

**Further Information and Application Forms Available from**

American Association for Cancer Research • Public Ledger Building, Suite 816 • 150 S. Independence Mall West  
Philadelphia, PA 19106-3483 • Telephone: (215) 440-9300 • FAX: (215) 440-9313 • E-mail: [aacr@aacr.org](mailto:aacr@aacr.org)

SOCIETÀ ITALIANA DEITUMORI  
SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI  
KIMMEL CANCER INSTITUTE, JEFFERSON MEDICAL COLLEGE  
SBARRO INSTITUTE FOR CANCER RESEARCH AND MOLECULAR MEDICINE

present:

*First Joint International Conference*

**“GENE TARGETS FOR CANCER TREATMENT”**

June 3-6, 1997 in Capri, Italy

*Chairpersons*

GIOVAN GIACOMO GIORDANO, M.D., Seconda Università degli Studi di Napoli  
CARLO M. CROCE, M.D., Kimmel Cancer Institute, Jefferson Medical College

---

**Environmental and Genetic Factors in Human Cancer**  
D.E. FISHER, B. HENDERSON, L.A. LOEB, M. TUCKER,  
G. THOMPSON, I.B. WEINSTEIN

**Oncogenes, Tumor Suppression Genes, The Cell Cycle and Cancer**  
C. BASILICO, C.M. CROCE, A. GIORDANO, J. SCHLESSINGER, S.I. REED,  
G. STEIN, J. SHAY

**Molecular Epidemiology**  
P.J. LANDRIGAN, C. HARRIS, L.L. ADAMS-CAMPBELL

**New Trends for Therapeutic Interventions**  
W.K. HONG, H. VITETTA, R. HERBERMAN

**Concluding Round Table Discussion:  
Present and Future Strategies in Preclinical and Clinical Treatment**

Moderators:

C.M. CROCE and F. CRUCITTI


---

*For more information please contact:*

USA: Barbara J. Soriano  
phone: 215-503-0781  
fax: 215-923-9626  
e-mail: [agiordan@lac.jci.tju.edu](mailto:agiordan@lac.jci.tju.edu)

Italy: Dr. Antonella Cicala  
phone: +39-(0)81-5511668  
fax: +39-(0)81-5528835

**Sbarro**  **Institute**  
Cancer Research Molecular Medicine



Portrayed on the cover are the recipients of the annual awards of the American Association for Cancer Research (AACR) for 1997. The awardees will present lectures during the 88th Annual Meeting, April 12–16, 1997, San Diego, California, at the San Diego Convention Center.

The G. H. A. Clowes Memorial Award is presented annually for outstanding accomplishments in basic cancer research. Supported by Eli Lilly and Company, this award is in memory of Dr. Clowes who was a founding member of the AACR and Research Director at Eli Lilly. The 1997 Clowes Award is presented to Stanley J. Korsmeyer, M.D. (*top right*), Professor of Medicine and Pathology at Washington University School of Medicine in St. Louis, and Investigator, Howard Hughes Medical Institute. Dr. Korsmeyer was instrumental in the discovery of several genes that appear to initiate apoptosis, as well as another gene that prevents it. Using transgenic mice, he demonstrated that a protein produced by the *bcl-2* gene (B-cell lymphoma) has the novel function of blocking the programmed death of cells rather than promoting their growth. Since then, many proteins have been implicated in the control of cell death, and this field continues to be one of the most active in cancer research. Dr. Korsmeyer's award lecture is entitled "Gene Family and the Regulation of Cell Death."

Awarded for outstanding research leading to improved clinical care in the field of cancer, the 1997 Richard and Hinda Rosenthal Foundation Award is presented to Daniel D. Von Hoff, M.D. (*top center*), CEO and Director of the Institute for Drug Development, Cancer Therapy and Research Center in San Antonio and Clinical Professor in the Division of Medical Oncology and Professor in the Department of Cellular and Structural Biology at The University of Texas Health Science Center at San Antonio. Dr. Von Hoff is being honored for his contributions to the development and optimal administration of several highly effective anticancer drugs. Dr. Von Hoff has been a pioneer in the development of several promising new agents, including a drug approved for the prevention of cardiotoxicity and several drugs under investigation for the treatment of leukemia, breast cancer, lymphoma, and prostate cancer. His award lecture is entitled "There Are No Bad Anticancer Agents—Only Bad Clinical Trial Designs." Dr. Von Hoff is the 21st recipient of the Rosenthal Award which is reserved for a scientist under the age of 51.

The Cornelius P. Rhoads Memorial Award recognizes outstanding

contributions to cancer research by a scientist under the age of 41. It honors Cornelius P. Rhoads, a founder and first director of the Sloan-Kettering Institute for Cancer Research. The 18th Rhoads Award recipient is Tyler Jacks, Ph.D. (*bottom right*), Assistant Professor in the Department of Biology and Center for Cancer Research at Massachusetts Institute of Technology and Assistant Investigator, Howard Hughes Medical Institute. Dr. Jacks is being honored for his contributions to the understanding of the functions of several tumor suppressor genes. Dr. Jacks has been one of the pivotal figures in the study of p53, a gene that normally keeps cell growth under control, but when mutated, spurs increased cell division contributing to tumor growth. He was also instrumental in the discovery that p53 plays a key role in triggering apoptosis. His award lecture is entitled "Tumor Suppressor Gene Mutations in Mice."

Established by Warner-Lambert, the Bruce F. Cain Memorial Award is presented for outstanding preclinical investigations leading to the improved care of cancer patients. This year's awardee is Leroy F. Liu, Ph.D. (*top left*), Professor and Chairman in the Department of Pharmacology at the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School. Dr. Liu was the first to discover mammalian type II DNA topoisomerases, which are targets for some of the most effective anticancer agents, such as etoposide and adriamycin. In addition, he was the first to identify mammalian type I DNA topoisomerases as novel targets for the promising new anticancer drugs irinotecan and topotecan. His current research focuses on developing new topoisomerase-targeting anticancer drugs with improved selectivity and potency, and elucidating their mechanisms of cell killing and resistance. Dr. Liu's award lecture is entitled "DNA Topoisomerases in Cell Proliferation and Cell Death."

Research Excellence in Cancer Epidemiology and Prevention is the focus of the 6th American Cancer Society Award presented to Henry T. Lynch, M.D. (*bottom center*), Professor of Medicine in the Department of Medicine at Creighton University School of Medicine in Omaha. Dr. Lynch has been one of the most influential figures worldwide in advancing the understanding of the hereditary basis of cancer, including certain breast, ovarian, and gastrointestinal cancers. His studies of families with extended hereditary nonpolyposis colorectal cancer (HNPCC) have provided the basis for awareness of this syndrome, also called Lynch syndrome. His award lecture is entitled "Etiology, Natural History, Management, and Molecular Genetics of HNPCC (Lynch Syndromes): Genetic Counseling Implications."

The AACR's newest award, the Joseph H. Burchenal AACR Clinical Research Award, honors an investigator for significant contributions to clinical care in the field of cancer. Sponsored by Bristol-Myers Squibb Oncology, this award was named after AACR Honorary Member and Past President Joseph H. Burchenal, M.D., who made significant contributions to the field of cancer chemotherapy during his long and distinguished career at Memorial Sloan-Kettering Cancer Institute. The second Burchenal Award will be presented to Ronald Levy, M.D. (*bottom left*), Chief of the Division of Oncology and Robert K. Summy and Helen K. Summy Professor at Stanford University School of Medicine. Dr. Levy is being honored for his contributions to the development and study of idiotypes as new therapeutic targets for the treatment of lymphoma. Lymphoma tumors each have a unique cell surface receptor, an idiotypic, which can be recognized by antibodies and T cells. In clinical trials by Dr. Levy, monoclonal antibodies and vaccines directed against idiotypes have produced profound and long-term remissions in lymphoma patients. Dr. Levy's award lecture is entitled "Antigen Receptors as Targets for Immunotherapy of Lymphoma."

The American Association for Cancer Research applauds the seminal work of these outstanding cancer researchers who have contributed so much to the conquest of cancer.